Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3322 USD | -2.29% | -10.67% | -65.58% |
05-08 | Apollomics, Inc. Appoints Robert Lin to the Board of Directors | CI |
05-08 | Apollomics, Inc. announced that it has received $5.75 million in funding | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-65.58% | 29.73M | - | ||
+9.42% | 115B | B+ | ||
+11.84% | 106B | B+ | ||
-1.05% | 21.96B | B | ||
-14.15% | 21.87B | B+ | ||
-5.29% | 19.21B | A- | ||
-4.16% | 18.08B | B | ||
-38.29% | 17.71B | A- | ||
+7.99% | 14.32B | C+ | ||
+36.24% | 12.42B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- APLM Stock
- Ratings Apollomics, Inc.